Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GRTS

Gritstone bio (GRTS) Stock Price, News & Analysis

Gritstone bio logo

About Gritstone bio Stock (NASDAQ:GRTS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.03
$0.63
52-Week Range
N/A
Volume
61.02 million shs
Average Volume
7.01 million shs
Market Capitalization
$3.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.17
Consensus Rating
Moderate Buy

Company Overview

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

GRTS Stock News Headlines

Gritstone Oncology Inc (GRTSQ)
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Gritstone bio, Inc. (GRTSQ)
Firm Retention Summary: Gritstone bio
Why Gritstone Bio (GRTS) Stock Is Down 64% Today
See More Headlines

GRTS Stock Analysis - Frequently Asked Questions

Gritstone bio, Inc. (NASDAQ:GRTS) released its earnings results on Tuesday, August, 13th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.12. The business earned $0.92 million during the quarter, compared to the consensus estimate of $2.77 million. Gritstone bio had a negative net margin of 910.50% and a negative trailing twelve-month return on equity of 328.51%.

Gritstone bio (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

Top institutional shareholders of Gritstone bio include Simplex Trading LLC. Insiders that own company stock include Andrew R Allen, Erin Jones, Matthew Hawryluk and Vassiliki Economides.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gritstone bio investors own include Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), American Water Works (AWK) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/13/2024
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRTS
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.17
High Stock Price Target
$5.00
Low Stock Price Target
$0.50
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$138.49 million
Net Margins
-910.50%
Pretax Margin
-910.50%

Debt

Sales & Book Value

Annual Sales
$496,000.00
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
N/A

Miscellaneous

Free Float
111,837,000
Market Cap
$3.50 million
Optionable
Optionable
Beta
0.49
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:GRTS) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners